Stockreport

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceuti [Read more]